Abstract
Abdominal aortic aneurysm (AAA) presents abnormal metabolism and co-occurs with cardiometabolic disorders, suggesting a shared genetic susceptibility. We investigated this commonality leveraging recent GWAS studies of AAA and 32 cardiometabolic traits (CMTs). Significant genetic correlations are found between AAA and 21 CMTs, among which are causal relationship with coronary artery disease, hypertension, lipid traits, and blood pressure. For each trait pair, we identified shared causal variants, genes, and pathways, which revealed cholesterol metabolism and immune responses were the shared most prominently. Additionally, we uncovered the tissue and cell type specificity in the shared signals, with strong enrichment across traits in liver, arteries, adipose tissues, macrophages, adipocytes, and fibroblasts. Finally, we leveraged drug-gene databases and identified several lipid-lowering drugs and antioxidants with high potential to treat AAA with comorbidities. Our study provides insight into the shared genetic mechanism for AAA and cardiometabolic traits and potential targets for pharmacological intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (No. 32270626), Greater Bay Area Research Institute of Precision Medicine (Guangzhou) Research Grants (I0005, R2001). We thank members of the Laboratory of Intelligent Computing in Biomedicine in the Greater Bay Area Institute of Precision Medicine (Guangzhou) for insightful discussions and suggestions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CVDKP,MEGASTROKE, UK Biobank, CARDIoGRAMplusC4D, Biobank Japan, DIAMANTE, CKDGen, AFGen Consortium, CDKP, FinnGen, GWAS Catalog, MAGIC, GLGC, ICBP, GIANT, Blood Cell Consortium (BCX)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abbreviations: CMT: cardiometabolic traits; CMD: cardiometabolic diseases; CVD: cardiovascular diseases; AAA: abdominal aortic aneurysm; AA: aortic aneurysm; TAA: thoracic aortic aneurysm; CAD: coronary artery disease; MI: myocardial infarction; HF: heart failure; CM: cardiomyopathy; AF: atrial fibrillation; stroke_AS: any stroke; stroke_AIS: any ischemic stroke; SAH: subarachnoid hemorrhage; ICH: intracerebral hemorrhage; TIA: transient ischemic attack; HT: hypertension; VTE: venous thromboembolism; PAD: peripheral artery disease; T2D: type 2 diabetes; CKD: chronic kidney disease;
MT: metabolic traits; FI: fasting insulin; FG: fasting glucose; 2hGlu: 2hr oral glucose challenge; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol; nonHDLC: non-high-density-lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; BMI: body mass index; WHR: wait to hip ratio; WHRadjbmi: WHR adjusted for BMI;
ICT: immune cell traits; WBC: white blood cells; BASO: basophil count; BASO%: basophil percentage of white blood cells; EO: eosinophil count; EO%: eosinophil percentage of white blood cells; LYMPH: lymphocyte count; LYMPH%: lymphocyte percentage of white blood cells; MONO: monocyte count; MONO%: monocyte percentage of white blood cells; NEUT: neutrophil count; NEUT%: neutrophil percentage of white blood cells.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
